ATE507881T1 - Galanthamin-derivate, verfahren zu deren herstellung und verwendung - Google Patents
Galanthamin-derivate, verfahren zu deren herstellung und verwendungInfo
- Publication number
- ATE507881T1 ATE507881T1 AT09472001T AT09472001T ATE507881T1 AT E507881 T1 ATE507881 T1 AT E507881T1 AT 09472001 T AT09472001 T AT 09472001T AT 09472001 T AT09472001 T AT 09472001T AT E507881 T1 ATE507881 T1 AT E507881T1
- Authority
- AT
- Austria
- Prior art keywords
- derivatives
- galanthamine
- galanthamin
- production
- inhibition
- Prior art date
Links
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical class O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 abstract 1
- 102100033639 Acetylcholinesterase Human genes 0.000 abstract 1
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract 1
- 108010053652 Butyrylcholinesterase Proteins 0.000 abstract 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 abstract 1
- 102100032404 Cholinesterase Human genes 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 229940022698 acetylcholinesterase Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960003980 galantamine Drugs 0.000 abstract 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 abstract 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BG10110141A BG110141A (en) | 2008-05-23 | 2008-05-23 | GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE507881T1 true ATE507881T1 (de) | 2011-05-15 |
Family
ID=40671399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT09472001T ATE507881T1 (de) | 2008-05-23 | 2009-02-24 | Galanthamin-derivate, verfahren zu deren herstellung und verwendung |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2123328B1 (de) |
| AT (1) | ATE507881T1 (de) |
| BG (1) | BG110141A (de) |
| DE (1) | DE602009001212D1 (de) |
| PL (1) | PL2123328T3 (de) |
| SI (1) | SI2123328T1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8247405B2 (en) * | 2008-12-10 | 2012-08-21 | Conopco, Inc. | Skin lightening compositions with acetylcholinesterase inhibitors |
| US20120184532A1 (en) * | 2009-07-23 | 2012-07-19 | Shire Llc | Galantamine amino acid and peptide prodrugs and uses thereof |
| BG67337B1 (bg) * | 2018-05-23 | 2021-06-15 | Софарма Ад | Метод за получаване на пречистен галантамин хидробромид |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR016751A1 (es) | 1996-11-22 | 2001-08-01 | Athena Neurosciences Inc | Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo |
| CA2272433A1 (en) | 1996-11-22 | 1998-05-28 | James E. Audia | N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and methods for inhibiting beta-amyloid peptide release and/or its synthesis |
| NZ516302A (en) * | 2000-03-31 | 2004-02-27 | Sanochemia Pharmazeutika Ag | Novel derivatives and analogues of galanthamin |
| US20040254146A1 (en) * | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
| US20050182044A1 (en) * | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
| WO2008022365A2 (de) * | 2006-08-24 | 2008-02-28 | Sanochemia Ltd. | Mittel zum beeinflussen der wirkungen von organophosphorverbindungen und verwendung von galanthamin, dessen derivaten und analoga zum herstellen solcher mittel |
-
2008
- 2008-05-23 BG BG10110141A patent/BG110141A/en unknown
-
2009
- 2009-02-24 SI SI200930042T patent/SI2123328T1/sl unknown
- 2009-02-24 EP EP09472001A patent/EP2123328B1/de active Active
- 2009-02-24 PL PL09472001T patent/PL2123328T3/pl unknown
- 2009-02-24 AT AT09472001T patent/ATE507881T1/de active
- 2009-02-24 DE DE602009001212T patent/DE602009001212D1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2123328B1 (de) | 2011-05-04 |
| DE602009001212D1 (de) | 2011-06-16 |
| PL2123328T3 (pl) | 2011-10-31 |
| EP2123328A1 (de) | 2009-11-25 |
| BG110141A (en) | 2009-12-31 |
| SI2123328T1 (sl) | 2011-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009127642A3 (en) | Use of lrrk2 inhibitors for neurodegenerative diseases | |
| UA83899C2 (uk) | Сполуки імідазолу для лікування нейродегенеративних розладів | |
| DE602005025642D1 (de) | 3-(heteroaryloxy)-2-alkyl-1-azabicycloalkylderivate als alpha.7-nachr-liganden zur behandlung von zns-erkrankungen | |
| MX2009008531A (es) | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. | |
| EA200971050A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений | |
| DE602005019078D1 (de) | Piperidine und verwandte verbindungen zur behandlung von alzheimer-krankheit | |
| CY1111327T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος | |
| ATE457985T1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| DE602005004416D1 (de) | Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit | |
| ATE432930T1 (de) | Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen | |
| ATE516290T1 (de) | Verfahren zur herstellung von buprenorphin und derivaten von buprenorphin | |
| ATE507881T1 (de) | Galanthamin-derivate, verfahren zu deren herstellung und verwendung | |
| TW200602297A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
| PH12012500640A1 (en) | Fluoro-substituted 3,5 - dicyano -4- (1h-indazol -5- yl) -2,6- dimethyl -1,4- dihydropyridine derivatives and methods of use thereof | |
| WO2005016267A3 (en) | Oxazole compounds for the treatment of neurodegenerative disorders | |
| ATE402150T1 (de) | Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen | |
| DE602005015697D1 (de) | Te zur behandlung von alzheimer-krankheit | |
| MX2009005351A (es) | Compuestos utiles para tratar trastornos neurodegenerativos. | |
| ES2333026T3 (es) | Derivados de ciclohexil-1,4-diamina sustituidos. | |
| ATE471322T1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| ATE407126T1 (de) | Herstellung von (s)-4-fluormethyl-dihydro-furan-2-on | |
| ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
| WO2007034326A3 (en) | Imidazole compounds for the treatment of neurological disorders | |
| BRPI0509582A (pt) | compostos de tiazol-amina e respectivas composições farmacêuticas | |
| WO2007147480A3 (en) | Polymorphic forms and process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 2123328 Country of ref document: EP |